Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Combined gene therapy effect revealed in syngeneic murine breast cancer models
February 14th, 2006
According to recently published research from the United States, oncolytic adenovirotherapy and TRAIL gene therapy have a combined effect in syngeneic murine breast cancer models. W. Guo and colleagues, M.D. Anderson Cancer Center, wrote, "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and oncolytic adenovirotherapy have been investigated extensively in xerographic human tumor models established in immunocompromised nude mice. However, the effects of these therapies on syngeneic murine tumors in immunocompetent settings were not well documented." "We hypothesized that TRAIL gene therapy used with an oncolytic adenovirus...
Source: Cancer Weekly (2006-02-14)
|
